Share Name Share Symbol Market Type Share ISIN Share Description
Vectura Group Plc LSE:VEC London Ordinary Share GB00BKM2MW97 ORD 0.0271P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.60 0.72% 83.60 83.00 83.40 85.10 82.50 85.10 431,960 16:29:59
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 160.5 -104.8 -13.2 - 513

Vectura Share Discussion Threads

Showing 9251 to 9270 of 9275 messages
Chat Pages: 371  370  369  368  367  366  365  364  363  362  361  360  Older
DateSubjectAuthorDiscuss
03/12/2019
18:37
One could argue that companies with too much money in the bank tend to be careless with it. Look what happened to GEC post Weinstock.
boadicea
03/12/2019
16:10
Agree popper, buybacks tend to be neutral in the short term, you could even argue that the company is devoid of ways to invest to grow or improve the business. One upside is it will improve the earnings/share figures.
diesel
03/12/2019
13:21
I fail to see how buying-back the shares is supposed to be a positive for shareholders. I understand that there will be fewer shares in circulation as a consequence and so each share is worth a fraction more of the company. But the company then has £10m less in the bank and so is worth £10m less. So we end up owning a fraction more of a company that is worth slightly less.
popper joe
03/12/2019
11:35
I still dont understand why VEC opted for a plan consisting of a special dividend, share consolidation and protracted share buyback instead of a straight forward tender offer. Makes me suspect they were badly advised by people who had something to gain ie inflated fees.
rogerrail
03/12/2019
08:19
No doubt you are right, polaris, but it just feels like it will be forever!
alexchry
03/12/2019
08:16
First month of buyback complete - just under £2 M committed for a little under 2.27 M shares at an average price of 85.86 p. HBM can't sell forever. The time is approaching where the selling pressure will finally dry up.
polaris
03/12/2019
07:29
Good news is exactly what’s needed and it’s been in extremely short supply for some considerable time forget HBM this is the sole reason we have performed so miserably for so long.
best1467
02/12/2019
22:32
So, if you plot HBM percentage (which automatically accommodates the consolidation) against date for the last 5 holding RNSs, and if you use a best fit line extrapolated forwards, the data indicate that HBM will have sold out, at or around late May/early June next year. And, at the present rate, JP Morgan, will complete phase I of the buyback at the expected date, which was published as 30th April. So, I'm expecting the share price to remain under pressure throughout the buyback. It will need good news to see significant upward price action during this time. Only a problem/issue if you're a short term trader though, I guess!?
frazboy
02/12/2019
21:51
The flip side it does benefit us in the long run if Vectura are buying back the shares at a lower level.
dp1umb
02/12/2019
20:12
It will be sods law that I sell out the next time it hits 90 and it bursts through the stale trading range
insideryou
01/12/2019
15:51
Let’s hope 2020 is the year of delivery it’s about time
best1467
29/11/2019
18:36
HBM continuing to sell ,almost certainly .Perhaps 2020 will be the year of the recovery & next Dec we will be over 150p ?
base7
29/11/2019
16:27
Why are there so many small sells, is this insti running down?
phillkay
29/11/2019
15:32
Recovery target I reckon soon.
phillkay
28/11/2019
11:54
Steady cash flow from the overall relationship with Novartis.Huge potential market in China 'fourth highest cause of death'China has a massive problem with adult smoking as well as the well publicised urban pollution.
fhmktg
28/11/2019
11:46
It's certainly a positive but expected
best1467
28/11/2019
10:43
How significant is the news from China?
dp1umb
27/11/2019
12:55
thanks polaris
richman777114
27/11/2019
09:18
A well-flagged announcement that tells us nothing new so not surprising there is little share price reaction for either company. We need to get some unexpected good news to get the share price moving, GSK dropping their appeal would be good start!
alexchry
27/11/2019
07:48
Hikma has submitted the CRL to FDA for VR315 (generic Advair). About time but positive news none the less.
polaris
Chat Pages: 371  370  369  368  367  366  365  364  363  362  361  360  Older
Your Recent History
LSE
VEC
Vectura
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191206 01:31:54